Osimertinib Plus Savolitinib Shows Activity in EGFR-Mutant, MET-Amplified NSCLC

April 8, 2019
Lecia V. Sequist, MD, MPH

Cancer Network spoke with Lecia V. Sequist, MD, MPH, about the TATTON study, which tested the combination of osimertinib and savolitinib in previously treated non–small-cell lung cancer patients.

Cancer Network spoke with Lecia V. Sequist, MD, MPH, about the TATTON study, which tested the combination of osimertinib and savolitinib in previously treated non–small-cell lung cancer patients.

Related Content:

AACR | Lung Cancer